https://www.selleckchem.com/pr....oducts/lonafarnib-sc
ypes. As MDT care becomes more widely adopted in the treatment of melanoma, accurate diagnosis and staging are important, as clinical outcomes for stage III disease vary widely by substage. Because ~50% of melanomas harbor BRAF mutations, testing is important for an informed treatment decision. Interdisciplinary physician-patient engagement throughout the course of treatment can improve comorbidity and adverse event management to optimize patients' treatment journeys. At diagnosis, the majority of patients with intrahepatic
Mi piace
Commento
Condividi
